Even if you don’t know much about the inner workings of generative AI models, you probably know they need a lot of memory. Hence, it is currently almost impossible to buy a measly stick of RAM without ...

Nvidia has a structured data enablement strategy. Nvidia provides libaries, software and hardware to index and search data faster. The Indexing and retrievals are way faster 10-40X faster in most ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

Creating a highly accurate geological model at a large scale presents a considerable challenge, primarily due to constraints imposed by sparse data availability. A promising strategy to mitigate these ...

Abstract: A general problem in multi-node systems is data synchronization, where the most used method uses synchronous data updating. All changes made by the user are immediately reflected in the data ...

Abstract: Data Structures and Algorithms (DSA) is fundamental to computer science education, yet novice learners face significant challenges in grasping abstract concepts and their system-level ...

Low-rank data analysis has emerged as a powerful paradigm across applied mathematics, statistics, and data science. With the rapid growth of modern datasets in size, dimensionality, and complexity, ...

Google launched four official and confirmed algorithmic updates in 2025, three core updates and one spam update. This is in comparison to last year, in 2024, where we had seven confirmed updates, then ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...